Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. Markets open in 5 hrs 22 mins
Russell 2000 Futures
Jupiter Wellness, Inc. (JUPW)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EST
56 reactions on $JUPW conversation
Sign in to post a message.
Is it a good buy now??
How are we doing today
Is this a good buy now at this level or wait more ?
$JUPW $IRNT $OTRK $MARK All in A/H’s ready for some short squeezes tomorrow 🤑🤑🤑
$OTRK 2 catalysts coming (Qtr Earnings Friday and Credit Suisse Conference Tuesday)
Short Interest 29.71% ~ 33.16%
% Insiders own 55.72%
% Institutions own 30.80%
52 Week Range $8.46 - $99.89
All Analysts have this as a strong buy and heavily oversold with fair price value of $16-$22.
Smells like a squeeze 👏👏👏
Also in $IRNT $JUPW as well
JUPITER, FL / November 11, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing cannabinoid receptor agonists for the treatment of eczema, actinic keratosis, burns, and herpes cold sores, announced that it has received an official written response from a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for JW-100, a topical drug the treatment of eczema.
The main purpose of the pre-IND meeting was to evaluate the drug development plan for JW-100.
Jupiter Wellness believes that the written response from the FDA supports the Company’s approach and its overall drug development strategy to enable the filing of an IND for its clinical studies on JW-100.
Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness, stated, “The pre-IND meeting written response marks an important milestone in the development of JW-100 for the treatment of eczema. We have obtained FDA concurrence and clear guidance on the proposed manufacturing, nonclinical pharmacology, and toxicology studies, and the Phase 1 clinical design.”
JW-100 met its primary endpoint in a recently completed Phase 1-equivalent international study in which Jupiter’s topical formulation cleared or reduced eczema following two weeks of use. These results suggest JW-100 may potentially prove superior to existing prescription drugs for the treatment of eczema in future clinical trials. The global eczema treatment market is valued at $10 billion and expected to grow at a CAGR of 13% from 2020-2025.
In at $2.02
10 dollars soon
7 dollars/ in February
Full-time employees: 5 lol
This name could very well catch on. In the afternoon, when the Reddit crowd wakes up to this, it could catch on fire... Also, there is, in fact, a good reason for it to spike...
Jupiter Wellness Announces Multi-Year Distribution Agreement with Rigour International for Expansion in Asia
Top percent stock gainers for Tues. (GTE made it)
so they buying justCBD
that's a game changer if true
Any body here..
What is the redemption info for the warrants?
10+ this week
Update from 10/19 up 10.44% and appears to be ready to run.
Anything negative is a short anything positive a bag holder. Normal
The monthly child tax credit payments are done—here’s what will replace it
BIC CEO details the $400 million market for temporary tattoos
Yahoo Finance Video
UK inflation hits 30-year high as cost of living squeeze looms
Yahoo Finance UK
Advertise with us
© 2022 Yahoo. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research